Clinical Trials /

TCR-engineered T Cells in Solid Tumors: IMA202-101



The study purpose is to establish the safety and tolerability of IMA202 product in patients with solid tumors that express melanoma-associated antigen 1 (MAGEA1).

Related Conditions:
  • Malignant Solid Tumor
Recruiting Status:



Phase 1

Trial Eligibility



  • Brief Title: TCR-engineered T Cells in Solid Tumors: IMA202-101
  • Official Title: Phase 1 Study Evaluating Genetically Modified Autologous T Cells Expressing a T-cell Receptor Recognizing a Cancer/Germline Antigen in Patients With Recurrent and/or Refractory Solid Tumors(ACTengine® IMA202-101)

Clinical Trial IDs

  • ORG STUDY ID: IMA202-101
  • NCT ID: NCT03441100


  • Solid Tumor, Adult
  • Refractory Cancer
  • Recurrent Cancer
  • Cancer


IMA202 ProductExperimental: IMA202 Product


The study purpose is to establish the safety and tolerability of IMA202 product in patients with solid tumors that express melanoma-associated antigen 1 (MAGEA1).

Detailed Description

      SCREENING: Patient eligibility will be determined by HLA (human leukocyte antigen) screening
      and a biopsy for biomarker screening. If the patient is eligible, white blood cells will be
      taken during leukapheresis for the manufacture of the IMA202 product.

      MANUFACTURING: IMA202 product will be made from the patient's white blood cells.

      TREATMENT: Lymphodepletion with cyclophosphamide and fludarabine will occur in the days
      before the IMA202 product infusion to improve the duration of time that IMA202 product stays
      in the body. The patient will be admitted to the hospital during the treatment.

      After the IMA202 product infusion, a low dose of IL-2 will be given twice daily for a period
      of time.

      Patients will be closely monitored for safety and for a total of 3 years post IMA202

Trial Arms

Experimental: IMA202 ProductExperimentalPre-conditioning by non-myeloablative chemotherapy with Fludarabine and Cyclophosphamide One dose of IMA202 product will be infused intravenously. Four dose levels will be evaluated. At least two patients per cohort will be treated. Post-infusion of IMA202 product, administration of low dose recombinant human interleukin-2
  • IMA202 Product

Eligibility Criteria

        Inclusion Criteria:

          -  Pathologically confirmed advanced and/or metastatic solid tumor

          -  Patients may enter screening procedure before, during, or after the last available
             indicated standard of care treatment. There is no limitation for prior anti cancer

          -  Eastern Cooperative Oncology Group (ECOG) performance status 0-1

          -  HLA phenotype positive for the study

          -  Measurable disease and accessible to biopsy

          -  Adequate pulmonary function per protocol

          -  Acceptable organ and bone marrow function per protocol

          -  Acceptable coagulation status per protocol

          -  Adequate hepatic function per protocol

          -  Adequate renal function per protocol

          -  Patient's tumor must express tumor antigen by qPCR using a fresh tumor biopsy specimen

          -  Life expectancy more than 3 months

          -  Confirmed availability of production capacities for IMA202 product

          -  Patients must have recurrent/progressing and/or refractory solid tumors and must have
             received or not be eligible for all available indicated standard of care treatment.

          -  For hepatocellular carcinoma (HCC) patients only, Child-Pugh score of ≤ 6

          -  IMA202 product must have passed all of the release tests

          -  Female patient of childbearing potential must use adequate contraception prior to
             study entry until 12 months after the infusion of IMA202

          -  Male patient must agree to use effective contraception or be abstinent while on study
             and for 6 months after the infusion of IMA202

          -  Hepatocellular carcinoma (HCC) patients with liver cirrhosis only - upper endoscopy is
             required within 6 months of study entry

          -  The patient must have recovered from any side effects of prior therapy to Grade 1 or
             lower (except for non-clinically significant toxicities; e.g., alopecia, vitiligo)
             prior to lymphodepletion. As determined by the investigator, the patient may still be
             eligible if the patient has not fully recovered from Grade ≥ 2 toxicities if these
             toxicities are not anticipated to further improve (e.g., chronic neuropathy) and such
             toxicities are not anticipated to worsen with the lymphodepletion therapy

        Exclusion Criteria:

          -  History of other malignancies (except for adequately treated basal or squamous cell
             carcinoma or carcinoma in situ) within the last 3 years

          -  Solid tumors with low likelihood of tumor biomarker expression per protocol

          -  Pregnant or breastfeeding

          -  Serious autoimmune disease Note: At the discretion of the investigator, these patients
             may be included if their disease is well controlled without the use of
             immunosuppressive agents.

          -  History of cardiac conditions as per protocol

          -  Prior stem cell transplantation or solid organ transplantation

          -  Concurrent severe and/or uncontrolled medical disease that could compromise
             participation in the study

          -  History of hypersensitivity to cyclophosphamide (CY), fludarabine (FLU), IL-2, or any
             of the rescue medications

          -  History of or current immunodeficiency disease or prior treatment compromising immune
             function at the discretion of the treating physician

          -  HIV infection, active hepatitis B virus (HBV), active hepatitis C virus (HCV)
             infection, ongoing active anti-HCV treatment or detectable HBV or HCV viral load at
             the most recent laboratory report. Patients with both HBV and HCV infections will be
             excluded from screening

               1. Patients with a history of HCV infection and with an undetectable viral load per
                  the most recent laboratory report and/or completed anti-HCV treatment but are HCV
                  antibody positive are permitted.

               2. History of treated HBV infection is permitted if the viral load is undetectable
                  per the most recent laboratory report. Note: HCC patients with controlled HBV
                  infection, as defined by resolved (anti-hepatitis B surface antigen [HBs-Ag]
                  antibody (Ab) negative, anti-core antigen [HBc Ag] Ab positive) or chronic stable
                  (anti HBs-Ag Ab positive) HBV infection will be eligible for screening. Patients
                  with active HBV infection who are not on anti-HBV treatment will be excluded.

          -  Any condition contraindicating leukapheresis, lymphodepletion, low-dose IL-2, and/or
             IMA202 treatment

          -  Patients with any active viral infection

          -  Patients with active brain metastases

        NOTE: Patients with a history of brain metastases may be eligible, if an imaging scan with
        contrast enhancement not older than 4 weeks is able to exclude the existence of currently
        active brain metastasis, and steroid therapy has been discontinued for ≥2 weeks.

          -  Treatment with protocol-defined excluded treatments, medical devices, and/or
             procedures per protocol

          -  Concurrent participation in an interventional part of another clinical trial.
Maximum Eligible Age:N/A
Minimum Eligible Age:18 Years
Eligible Gender:All
Healthy Volunteers:No

Primary Outcome Measures

Measure:Incidence of adverse events (AE)
Time Frame:up to 3 years post treatment
Safety Issue:

Secondary Outcome Measures

Measure:Persistence of T-cells
Time Frame:up to 3 years post treatment
Safety Issue:
Measure:Tumor response per Response Evaluation Criteria In Solid Tumors (RECIST) 1.1 and immune-related RECIST (irRECIST)
Time Frame:up to 12 months
Safety Issue:


Phase:Phase 1
Primary Purpose:Interventional
Overall Status:Recruiting
Lead Sponsor:Immatics US, Inc.

Trial Keywords

  • T-Cell therapy
  • Immunotherapy
  • Adoptive cellular therapy
  • T-Cell Receptor
  • Cell Therapy
  • Cytotherapy
  • IMA202

Last Updated

August 25, 2021